SPY447.17-0.71 -0.16%
DIA348.18-0.64 -0.18%
IXIC15,181.92+20.40 0.13%

BRIEF-Takeda Provides Update On Phase 3 PANTHER (Pevonedistat-3001) Trial

reuters.com · 09/01/2021 16:54
BRIEF-Takeda Provides Update On Phase 3 PANTHER (Pevonedistat-3001) Trial

- Takeda Pharmaceutical Co Ltd TAK:

  • TAKEDA PROVIDES UPDATE ON PHASE 3 PANTHER (PEVONEDISTAT-3001) TRIAL

  • TAKEDA PHARMACEUTICAL - PHASE 3 PANTHER STUDY DID NOT ACHIEVE PRE-DEFINED STATISTICAL SIGNIFICANCE FOR PRIMARY ENDPOINT OF EVENT-FREE SURVIVAL

  • TAKEDA PHARMACEUTICAL - TAKEDA WILL WORK WITH INVESTIGATORS WHO WILL DETERMINE MOST APPROPRIATE ACTION FOR EACH INDIVIDUAL PATIENT ENROLLED IN STUDY.

Source text for Eikon: ID:nBw3PCM24a

Further company coverage: TAK


((Reuters.Briefs@thomsonreuters.com;))